PL372773A1 - Sposób podawania doustnego epotilonów - Google Patents

Sposób podawania doustnego epotilonów

Info

Publication number
PL372773A1
PL372773A1 PL03372773A PL37277303A PL372773A1 PL 372773 A1 PL372773 A1 PL 372773A1 PL 03372773 A PL03372773 A PL 03372773A PL 37277303 A PL37277303 A PL 37277303A PL 372773 A1 PL372773 A1 PL 372773A1
Authority
PL
Poland
Prior art keywords
epothilones
oral administration
oral
administration
Prior art date
Application number
PL03372773A
Other languages
English (en)
Inventor
Francis Y.L. Lee
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL372773A1 publication Critical patent/PL372773A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL03372773A 2002-04-04 2003-04-01 Sposób podawania doustnego epotilonów PL372773A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37010402P 2002-04-04 2002-04-04

Publications (1)

Publication Number Publication Date
PL372773A1 true PL372773A1 (pl) 2005-08-08

Family

ID=28792029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372773A PL372773A1 (pl) 2002-04-04 2003-04-01 Sposób podawania doustnego epotilonów

Country Status (9)

Country Link
US (1) US6936628B2 (pl)
EP (1) EP1492529A1 (pl)
JP (1) JP2005527576A (pl)
AU (1) AU2003226189A1 (pl)
IS (1) IS7481A (pl)
NO (1) NO20044452L (pl)
PL (1) PL372773A1 (pl)
TW (1) TW200403994A (pl)
WO (1) WO2003084536A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
ES2752452T3 (es) 2002-05-14 2020-04-06 Dupont Nutrition Usa Inc Composiciones de hidrocoloides de celulosa microcristalinas codesgastadas por atrición y método para su fabricación
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
FR2878443B1 (fr) * 2004-08-03 2009-01-16 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation
TW200631609A (en) * 2004-11-18 2006-09-16 Bristol Myers Squibb Co Enteric coated bead comprising ixabepilone, and preparation and administration thereof
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US20060255258A1 (en) * 2005-04-11 2006-11-16 Yongdong Wang Chromatographic and mass spectral date analysis
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
WO2008057267A2 (en) * 2006-10-27 2008-05-15 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
US8632819B2 (en) * 2009-12-22 2014-01-21 Fmc Corporation Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2013052114A1 (en) 2011-10-05 2013-04-11 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
US9055757B2 (en) 2011-10-05 2015-06-16 Fmc Corporation Stabilizer composition of co-attrited microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
BR112014013792B8 (pt) 2011-12-09 2020-11-10 Dupont Nutrition Usa Inc composição estabilizadora co-atritada compreendendo carboximetilcelulose de alto grau de substituição e baixa viscosidade, alimento, composição industrial, e, método para fazer a composição estabilizadora
GB2595203A (en) 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation
CZ2020287A3 (cs) 2020-05-20 2021-12-01 Mendelova Univerzita V Brně Způsob přípravy nanokompozitního materiálu na bázi redukovaného grafen oxidu, dusičnanu stříbrného a octanu měďnatého, nanokompozitní materiál, přípravek jej obsahující a jeho použití
AU2021337086B2 (en) * 2020-09-02 2024-02-29 Beijing Biostar Pharmaceuticals Co., Ltd. Solid oral formulation of utidelone

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5671397A (en) * 1993-12-27 1997-09-23 At&T Global Information Solutions Company Sea-of-cells array of transistors
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
EP0923583A1 (de) 1996-08-30 1999-06-23 Novartis AG Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19880193D2 (de) 1997-02-25 2000-08-24 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte Epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
HUP0101564A3 (en) 1998-02-05 2002-06-28 Novartis Ag Compositions containing epothilone
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
CA2356360A1 (en) 1998-12-23 2000-07-06 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
SK11852001A3 (sk) 1999-02-18 2002-04-04 Schering Aktiengesellschaft Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
SK287200B6 (sk) * 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
JP2004522771A (ja) * 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー 治療抵抗性腫瘍の処置用エポチロン誘導体
RU2003128311A (ru) * 2001-02-20 2005-03-10 Бристол-Маерс Сквибб Компани (Us) Способ лечения резистентных опухолей с применением аналогов эпотилона
HU230273B1 (hu) * 2001-03-14 2015-11-30 Bristol-Myers Squibb Company Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives

Also Published As

Publication number Publication date
TW200403994A (en) 2004-03-16
JP2005527576A (ja) 2005-09-15
AU2003226189A1 (en) 2003-10-20
NO20044452L (no) 2004-12-07
WO2003084536A1 (en) 2003-10-16
EP1492529A1 (en) 2005-01-05
US6936628B2 (en) 2005-08-30
IS7481A (is) 2004-09-30
US20030220378A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
PL372773A1 (pl) Sposób podawania doustnego epotilonów
GB0217225D0 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
PL377495A1 (pl) Stały lek do stosowania doustnego
GB0209668D0 (en) Oral devices
IL166337A0 (en) Oral administration of calctionin
GB0202900D0 (en) Novel formulations of drugs
GB0325383D0 (en) Oral formulations
ZA200603542B (en) Oral formulations of desoxypeganine and uses thereof
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
ZA200409624B (en) Pharmaceutical salts of reboxetine
AU2003298725A8 (en) Preparation of metallotexaphyrins
GB0605419D0 (en) Oral Hygiene Arches
GB0225702D0 (en) Oral formulation of moisutre-sensitive drugs
IL165843A0 (en) Popping oral administration form
HK1078258A (en) Oral administration of calcitonin
AU2002241935A1 (en) Pharmaceutical forms of epothilones for oral administration
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
IL147496A (en) Preparation of a therapeutic composition
HK1072196A (en) Oral administration of interferon-tau
TW559057U (en) Improved structure of camera for oral use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)